68Ga-DOTATATE PET Scan in Neuroendocrine Cancer

Eligible participants will undergo baseline assessments at enrollment. Study participants
will receive a one-time administration of 68GaDOTATATE and undergo a PET/CT imaging study.
Scans will be performed with "negative" oral contrast (e.g. Volumen™ or equivalent), as many
NETs involve the GI tract.

Inclusion Criteria:

- Known diagnosis of neuroendocrine tumor

- At least 18 years of age

- Able to provide informed consent

- Karnofsky score greater than 50

- Females of childbearing potential must have a negative pregnancy test at
screening/baseline

Exclusion Criteria:

- Serum creatinine >3.0 mg/dL (270 μM/L)

- Hepatic enzyme levels more than 5 times upper limit of normal.

- Known severe allergy or hypersensitivity to IV radiographic contrast.

- Use of any other investigational product or device within 30 days prior to dosing, or
known requirement for any other investigational agent prior to completion of all
scheduled study assessments.

- Patients with a body weight of 400 pounds or more or not able to enter the bore of
the PET/CT scanner due to BMI, because of the compromise in image quality with CT,
PET/CT and MRI that will result.

- Inability to lie still for the entire imaging time (e.g. cough, severe arthritis,
etc.).

- Inability to complete the needed investigational and standard-of-care imaging
examinations due to other reasons (severe claustrophobia, radiation phobia, etc.)

- Recognized concurrent active infection

- Any additional medical condition, serious intercurrent illness, or other extenuating
circumstance that, in the opinion of the Investigator, may significantly interfere
with study compliance.